Integrating oncolytic adenoviruses into combination cancer therapy: Mechanisms, advances and clinical outlook

Abstract

Background: Cancer represents a major global public health issue, and recent research has focused on improving the efficacy of existing therapeutic approaches. In this context, oncolytic viruses have emerged as promising treatment options for advanced and treatment-resistant malignancies. Among them, adenoviruses are the most extensively studied due to their favourable safety profile, biological versatility and ease of genetic modification to enhance therapeutic performance.

Main body: Combination-based strategies integrating virotherapy with chemotherapy, radiotherapy or immunotherapy have been widely investigated to further improve anti-tumour efficacy. These approaches act through complementary and synergistic mechanisms, where chemotherapy can promote viral replication and increase tumour cell susceptibility through deoxyribonucleic acid (DNA) damage and transient immunomodulation, while radiotherapy enhances immunogenic tumour cell death by inducing sustained DNA damage. In parallel, immunotherapy—particularly immune checkpoint inhibition—can strengthen anti-tumour immunity by reversing T-cell exhaustion and increasing CD8⁺ T-cell infiltration and effector function. Collectively, these interactions amplify both direct viral oncolysis and immune-mediated tumour clearance. Additionally, clinical trial data suggest that intravenous administration of oncolytic adenoviruses may provide greater systemic antit-umour activity compared with intratumoural delivery, albeit with increased toxicity relative to localised injection.

Conclusion: Oncolytic adenoviruses have emerged as promising treatment options for advanced and treatment-resistant malignancies, particularly when integrated with chemotherapy, radiotherapy or immunotherapy. However, most studies included are early-phase trials conducted in small patient cohorts, underscoring the need for further research to better define safety profiles, long-term adverse effects, and the underlying mechanisms driving therapeutic response.

Keywords

adenoviruses / combination cancer therapy / oncolytic viruses / virotherapy

References

[1] Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A. Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discov Oncol. 2025; 16(1): 607. https://doi.org/10.1007/s12672-025-02198-8

[2] Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023; 9(2): 122-139. https://doi.org/10.1016/j.trecan.2022.10.003

[3] Iyer M, Ravichandran N, Karuppusamy PA, et al. Molecular insights and promise of oncolytic virus based immunotherapy. Adv Protein Chem Struct Biol. 2024; 140: 419-492. https://doi.org/10.1016/bs.apcsb.2023.12.007

[4] Hua X, Xuan S, Tang Y, et al. Progression of oncolytic virus in liver cancer treatment. Front Oncol. 2024; 14:1446085. https://doi.org/10.3389/fonc.2024.1446085

[5] Muthukutty P, Yoo SY. Oncolytic virus engineering and utilizations: cancer immunotherapy perspective. Viruses. 2023; 15:1645. https://doi.org/10.3390/v15081645

[6] Zhao Y, Liu Z, Li L, et al. Oncolytic adenovirus: prospects for cancer immunotherapy. Front Microbiol. 2021; 12:707290. https://doi.org/10.3389/fmicb.2021.707290

[7] Hagedorn C, Kreppel F. Capsid engineering of adenovirus vectors: overcoming early vector–host interactions for therapy. Hum Gene Ther. 2017; 28(10): 820-832. https://doi.org/10.1089/hum.2017.139

[8] Bressy C, Benihoud K. Association of oncolytic adenoviruses with chemotherapies: an overview and future directions. Biochem Pharmacol. 2014; 90(2): 97-106. https://doi.org/10.1016/j.bcp.2014.05.003

[9] O'Cathail SM, Pokrovska TD, Maughan TS, Fisher KD, Seymour LW, Hawkins MA. Combining oncolytic adenovirus with radiation—a paradigm for the future of radiosensitisation. Front Oncol. 2017; 7:153. https://doi.org/10.3389/fonc.2017.00153

[10] Cheng C, Wang Q, Zhang S. Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms. Front Immunol. 2025; 16:1610858. https://doi.org/10.3389/fimmu.2025.1610858

[11] Tysome JR, Li X, Wang S, et al. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity. Clin Cancer Res. 2012; 18(24): 6679-6689. https://doi.org/10.1158/1078-0432.CCR-12-0979

[12] Nadafi R, Dong W, van Beusechem VW. Immunological impact of oncolytic adenoviruses on cancer therapy: clinical insights. Eur J Immunol. 2025; 55(7):e70024. https://doi.org/10.1002/eji.70024

[13] Fang L, Yuan S, Wang M, et al. Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-γ promotes CAR-T infiltration and proliferation in vivo to eradicate local and distal tumors. Cell Death Discov. 2023; 9(1): 328. https://doi.org/10.1038/s41420-023-01626-4

[14] Rowe WP, Huebner RJ, Gilmore LK, et al. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med. 1953; 84: 570-573.

[15] van Oostrum J, Burnett RM. Molecular composition of the adenovirus type 2 virion. J Virol. 1985; 56: 439-448.

[16] Stewart PL, Fuller SD, Burnett RM. Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J. 1993; 12: 2589-2599.

[17] Meier O, Boucke K, Hammer SV, et al. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J Cell Biol. 2002; 158: 1119-1131.

[18] Abudoureyimu M, Lai Y, Tian C, Wang T, Wang R, Chu X. Oncolytic adenovirus-a nova for gene-targeted oncolytic viral therapy in HCC. Front Oncol. 2019; 9:1182. https://doi.org/10.3389/fonc.2019.01182

[19] Li S, Ou M, Wang G, Tang L. Application of conditionally replicating adenoviruses in tumor early diagnosis technology, gene-radiation therapy and chemotherapy. Appl Microbiol Biotechnol. 2016; 100: 8325-8335. https://doi.org/10.1007/s00253-016-7806-z

[20] Mantwill K, Klein FG, Wang D, et al. Concepts in oncolytic adenovirus therapy. Int J Mol Sci. 2021; 22(19):10522. https://doi.org/10.3390/ijms221910522

[21] Leitner S, Sweeney K, Oberg D, et al. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res. 2009; 15(5): 1730-1740. https://doi.org/10.1158/1078-0432.CCR-08-2008

[22] Jadhav A, Patel T. A comprehensive review redefining viruses as therapeutic agents in cancer treatment. Discov Oncol. 2025; 16(1): 2342. https://doi.org/10.1007/s12672-025-03973-3

[23] Schoggins JW, Falck-Pedersen E. Fibre and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity. J Virol. 2006; 80(21): 10634-10644. https://doi.org/10.1128/JVI.01359-06

[24] Li X, Liu Y, Wen Z, et al. Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo. Mol Cancer. 2010; 9:10. https://doi.org/10.1186/1476-4598-9-10

[25] Rojas JJ, Cascallo M, Guedan S, et al. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Ther. 2009; 16(12): 1441-1451. https://doi.org/10.1038/gt.2009.103

[26] Cerullo V, Diaconu I, Ugolini M, et al. Oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor (GM-CSF) for treatment of cancer. Mol Ther. 2009; 17: S106-S107.

[27] Pesonen S, Diaconu I, Kangasniemi L, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 2012; 72(7): 1621-1631. https://doi.org/10.1158/0008-5472.CAN-11-3001

[28] Ramos-Gonzalez MR, Tarique M, Batra L, et al. Oncolytic adenovirus armed with a novel agonist of the CD137 immune checkpoint stimulator suppresses tumor growth. Vaccines (Basel). 2024; 12(3):340. https://doi.org/10.3390/vaccines12030340

[29] Fang L, Yuan S, Wang M, et al. Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-γ promotes CAR-T infiltration and proliferation in vivo to eradicate local and distal tumors. Cell Death Discov. 2023; 9(1): 328. https://doi.org/10.1038/s41420-023-01626-4

[30] Ono R, Tokuoka S, Tachibana M, Ishii KJ, Sakurai F, Mizuguchi H. Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity. J Immunother Cancer. 2025; 13(7):e006558. https://doi.org/10.1136/jitc-2022-006558

[31] Zhang Y, He B, Zou P, et al. Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors. J Immunother Cancer. 2025; 13:e010767. https://doi.org/10.1136/jitc-2024-010767

[32] Wang S, Kong L, Wang L, et al. Viral expression of NE/PPE enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting TAM M1 polarization to reverse insufficient effector memory/effector CD8⁺ T cell infiltration. J Exp Clin Cancer Res. 2025; 44(1): 97. https://doi.org/10.1186/s13046-025-03358-y

[33] Kang X, Han Y, Wu M, et al. In situ blockade of TNF-TNFR2 axis via oncolytic adenovirus improves antitumor efficacy in solid tumors. Mol Ther. 2025; 33(2): 670-687. https://doi.org/10.1016/j.ymthe.2024.12.011

[34] Morita D, Rosewell Shaw A, Biegert G, et al. Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer. 2024; 12(12):e009741. https://doi.org/10.1136/jitc-2024-009741

[35] Cheng Y, Zhao Y, Liu Y, et al. Durable antitumor response via an oncolytic virus encoding decoy-resistant IL-18. J Immunother Cancer. 2024; 12(12):e009716. https://doi.org/10.1136/jitc-2024-009716

[36] Zhu H, Zhang W, Guo Q, Fan R, Luo G, Liu Y. Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response. J Immunother Cancer. 2024; 12(11):e009901. https://doi.org/10.1136/jitc-2024-009901

[37] Basnet S, Van der Heijden M, Quixabeira DCA, et al. Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine. Mol Ther. 2024; 32(9): 3114-3127. https://doi.org/10.1016/j.ymthe.2024.06.029

[38] Schäfer TE, Knol LI, Haas FV, et al. Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. EBioMedicine. 2024; 105:105219. https://doi.org/10.1016/j.ebiom.2024.105219

[39] Lee DH, Yoo JK, Um KH, et al. Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment. J Exp Clin Cancer Res. 2024; 43(1): 170. https://doi.org/10.1186/s13046-024-03088-7

[40] Dong J, Kong L, Wang S, et al. Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice. J Exp Clin Cancer Res. 2024; 43(1): 102. https://doi.org/10.1186/s13046-024-03011-0

[41] Feola S, Hamdan F, Russo S, et al. Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors. J Immunother Cancer. 2024; 12(3):e008342. https://doi.org/10.1136/jitc-2023-008342

[42] Meng Y, Liu H, Zhu H, et al. RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment. J Immunother Cancer. 2024; 12(1):e007171. https://doi.org/10.1136/jitc-2023-007171

[43] Wang S, Yan W, Kong L, et al. Oncolytic viruses engineered to enforce cholesterol efflux restore tumor-associated macrophage phagocytosis and anti-tumor immunity in glioblastoma. Nat Commun. 2023; 14(1): 4367. https://doi.org/10.1038/s41467-023-39683-z

[44] Ban W, Sun M, Huang H, et al. Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy. Nat Commun. 2023; 14(1): 2933. https://doi.org/10.1038/s41467-023-38679-z

[45] Hu S, Xu J, Wang Z, et al. SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication. J Immunother Cancer. 2026; 14(1):e013550. https://doi.org/10.1136/jitc-2025-013550

[46] Russo S, Giannoula Y, Feola S, et al. Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy. J Immunother Cancer. 2025; 13(11):e012138. https://doi.org/10.1136/jitc-2025-012138

[47] Chen Y, Ren L, Li X, et al. Novel oncolytic adenovirus-based PEPvIII vaccine displays a super antitumor effect in glioma models. J Immunother Cancer. 2025; 13(9):e010750. https://doi.org/10.1136/jitc-2024-010750

[48] Wang G, Zhang Z, Zhong K, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther. 2023; 31(1): 134-153. https://doi.org/10.1016/j.ymthe.2022.08.021

[49] Jiang S, Xu H, Sun M, et al. Interleukin-8-induced tumor self-rampart spatially confines oncolytic virotherapy in glioblastoma. Neuro Oncol. 2026; 28(3): 643-658. https://doi.org/10.1093/neuonc/noaf276

[50] Liu K, Kong L, Cui H, et al. Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell Rep Med. 2024; 5(10):101751. https://doi.org/10.1016/j.xcrm.2024.101751

[51] Wennier ST, Liu J, McFadden G. Bugs and drugs: oncolytic virotherapy in combination with chemotherapy. Curr Pharm Biotechnol. 2012; 13(9): 1817-1833. https://doi.org/10.2174/138920112800958850

[52] Kang X, Li Y, Han Y, et al. Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer. Mol Ther. 2025; 33(9): 4600-4617. https://doi.org/10.1016/j.ymthe.2025.05.032

[53] Chen Y, Wang J, Huang Y, et al. An oncolytic system produces oxygen selectively in pancreatic tumor cells to alleviate hypoxia and improve immune activation. Pharmacol Res. 2024; 199:107053. https://doi.org/10.1016/j.phrs.2023.107053

[54] Guo C, Gao T, Xue B, et al. In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. Cell Rep Med. 2025; 6(10):102399. https://doi.org/10.1016/j.xcrm.2025.102399

[55] Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018; 18(2): 171-176.

[56] Russell L, Peng KW. The emerging role of oncolytic virus therapy against cancer. Chin Clin Oncol. 2018; 7(2): 16.

[57] McSharry BP, Burgert H-G, Owen DP, et al. adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B. J Virol. 2008; 82(9): 4585-4594.

[58] Zhang J, Zhang Q, Liu Z, et al. Efficacy and safety of recombinant human adenovirus type 5 (H101) in persistent, recurrent, or metastatic gynecologic malignancies: a retrospective study. Front Oncol. 2022; 12:877155; https://doi.org/10.3389/fonc.2022.877155

[59] Zhang R, Cui Y, Guan X, Jiang X. A recombinant human adenovirus type 5 (H101) combined with chemotherapy for advanced gastric carcinoma: a retrospective cohort study. Front Oncol. 2021; 11:752504. https://doi.org/10.3389/fonc.2021.752504

[60] Yi L, Ning Z, Xu L, et al. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study. ESMO Open. 2024; 9(2):102239. https://doi.org/10.1016/j.esmoop.2024.102239

[61] Xia ZJ, Chang JH, Zhang L, et al. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. Ai Zheng. 2004; 23(12): 1666-1670.

[62] Lei J, Li QH, Yang JL, et al. The antitumor effects of oncolytic adenovirus H101 against lung cancer. Int J Oncol. 2015; 47(2): 555-562. https://doi.org/10.3892/ijo.2015.3045

[63] Qiao C, Xu Y, He Y, Cai Z, Wang H. Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells. Oncol Res. 2025; 33(5): 1161-1172.

[64] Wang D, Porter CE, Lim B, et al. Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023; 9(13):eade6790. https://doi.org/10.1126/sciadv.ade6790

[65] Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z. Intra-tumor injection of H101, a recombinant Ad, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol. 2004; 10(24): 3634-3638. https://doi.org/10.3748/wjg.v10.i24.3634

[66] Duan C, Liu X. Recombinant human adenovirus type 5 administration for the treatment of malignant ascites or pleural effusion in cancer patients: a meta-analysis. Front Oncol. 2025; 15:1592995. https://doi.org/10.3389/fonc.2025.1592995

[67] Gao P, Ding G, Wang L. The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis. Transl Cancer Res. 2021; 10(10): 4290-4302.

[68] Wenthe J, Naseri S, Labani-Motlagh A, et al. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. Cancer Immunol Immunother. 2021; 70(10): 2851-2865. https://doi.org/10.1007/s00262-021-02895-7

[69] Delolimogene mupadenorepvec. In: NCI Drug Dictionary. National Cancer Institute; 2024. Accessed February 1, 2026. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/delolimogene-mupadenorepvec

[70] Eriksson E, Milenova I, Wenthe J, et al. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin Cancer Res. 2017; 23(19): 5846-5857. https://doi.org/10.1158/1078-0432.CCR-17-0285

[71] Eriksson E, Moreno R, Milenova I, et al. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment. Gene Ther. 2017; 24(2): 92-103. https://doi.org/10.1038/gt.2016.80

[72] Benedict CA, Norris PS, Prigozy TI, et al. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J Biol Chem. 2001; 276(5): 3270-3278. https://doi.org/10.1074/jbc.M008218200

[73] Wenthe J, Naseri S, Hellström AC, Wiklund HJ, Eriksson E, Loskog A. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40. Cancer Gene Ther. 2020; 27(12): 948-959. https://doi.org/10.1038/s41417-020-0176-9

[74] Ulasov IV, Zhu ZB, Tyler MA, et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther. 2007; 18(7): 589-602. https://doi.org/10.1089/hum.2007.002

[75] Qiao D, Meyer K, Mundhenke C, Drew SA, Friedl A. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells. Specific role for glypican-1 in glioma angiogenesis. J Biol Chem. 2003; 278(18): 16045-16053. https://doi.org/10.1074/jbc.M211259200

[76] Staba MJ, Wickham TJ, Kovesdi I, Hallahan DE. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther. 2000; 7(1): 13-19. https://doi.org/10.1038/sj.cgt.7700104

[77] Van Houdt WJ, Haviv YS, Lu B, et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg. 2006; 104(4): 583-592. https://doi.org/10.3171/jns.2006.104.4.583

[78] Webb MJ, Sener U, Vile RG. Current status and challenges of oncolytic virotherapy for the treatment of glioblastoma. Pharmaceuticals (Basel). 2023; 16(6):793. https://doi.org/10.3390/ph16060793

[79] Ahmed AU, Thaci B, Alexiades NG, et al. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther. 2011; 19(9): 1714-1726. https://doi.org/10.1038/mt.2011.100

[80] Thaci B, Ahmed A, Ulasov I et al. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther. 2012; 19: 431-442. https://doi.org/10.1038/cgt.2012.21

[81] Morshed RA, Gutova M, Juliano J, et al. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction. Cancer Gene Ther. 2015; 22(1): 55-61. https://doi.org/10.1038/cgt.2014.72

[82] Mooney R, Majid AA, Batalla-Covello J, et al. Enhanced delivery of oncolytic adenovirus by neural stem cells for treatment of metastatic ovarian cancer. Mol Ther Oncolytics. 2018; 12: 79-92. https://doi.org/10.1016/j.omto.2018.12.003

[83] Oncolytic adenovirus Ad5-DNX-2401. In: NCI Drug Dictionary. National Cancer Institute; 2025. Accessed February 1, 2026. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tasadenoturev

[84] Martínez-Vélez N, Garcia-Moure M, Marigil M, et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun. 2019; 10(1): 2235. https://doi.org/10.1038/s41467-019-10043-0

[85] Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018; 36(14): 1419-1427. https://doi.org/10.1200/JCO.2017.75.8219

[86] Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007; 67(24): 11499-11504. https://doi.org/10.1158/0008-5472.CAN-07-5312

[87] Lang FF. Phase 1b open-label randomized study of the oncolytic adenovirus DNX-2401 administered with or without interferon-γ for recurrent glioblastoma. J Clin Oncol. 2017; 35(15_suppl):2002. https://doi.org/10.1200/JCO.2017.35.15_suppl.2002

[88] Havunen R, Kalliokoski R, Siurala M, et al. Cytokine-coding oncolytic adenovirus TILT-123 is safe, selective, and effective as a single agent and in combination with immune checkpoint inhibitor anti-PD-1. Cells. 2021; 10(2):246. https://doi.org/10.3390/cells10020246

[89] Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther. 2003; 8(3): 449-458. https://doi.org/10.1016/s1525-0016(03)00200-4

[90] Wang H, Li ZY, Liu Y, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 2011; 17(1): 96-104. https://doi.org/10.1038/nm.2270

[91] Havunen R, Siurala M, Sorsa S, et al. Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy. Mol Ther Oncolytics. 2016; 4: 77-86. https://doi.org/10.1016/j.omto.2016.12.004

[92] Watanabe K, Luo Y, Da T, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 2018; 3(7):e99573. https://doi.org/10.1172/jci.insight.99573

[93] Cervera-Carrascon V, Siurala M, Santos JM, et al. TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology. 2018; 7(5):e1412902. https://doi.org/10.1080/2162402X.2017.1412902

[94] Cervera-Carrascon V, Quixabeira DCA, Havunen R, et al. Comparison of clinically relevant oncolytic virus platforms for enhancing T cell therapy of solid tumors. Mol Ther Oncolytics. 2020; 17: 47-60. https://doi.org/10.1016/j.omto.2020.03.003

[95] Jirovec E, Quixabeira DCA, Clubb JHA, et al. Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors. J Exp Clin Cancer Res. 2024; 43(1): 297. https://doi.org/10.1186/s13046-024-03219-0

[96] Pakola SA, Peltola KJ, Clubb JHA, et al. Safety, efficacy, and biological data of T-cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial. Clin Cancer Res. 2024; 30(17): 3715-3725. https://doi.org/10.1158/1078-0432.CCR-23-3874

[97] Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 2010; 18(10): 1874-1884.

[98] Ranki T, Pesonen S, Hemminki A, et al. Phase I study with ONCOS-102 for the treatment of solid tumors—an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer. 2016; 4: 17. https://doi.org/10.1186/s40425-016-0121-5

[99] Ponce S, Cedrés S, Ricordel C, et al. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. J Immunother Cancer. 2023; 11(9):e007552. https://doi.org/10.1136/jitc-2023-007552

[100] Kuryk L, Møller AW, Jaderberg M. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. Oncoimmunology. 2018; 8(2):e1532763. https://doi.org/10.1080/2162402X.2018.1532763

[101] Kuryk L, Haavisto E, Garofalo M, et al. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model. Int J Cancer. 2016; 139(8): 1883-1893. https://doi.org/10.1002/ijc.30228

[102] Guan J, Sun K, Guerrero CA, et al. A phase 2 study of in situ oncolytic virus therapy and stereotactic body radiation therapy followed by pembrolizumab in metastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2024; 118(5): 1531-1540. https://doi.org/10.1016/j.ijrobp.2023.08.044

[103] Windeatt S, Southgate TD, Dewey RA, et al. Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas. J Clin Endocrinol Metab. 2000; 85(3): 1296-1305. https://doi.org/10.1210/jcem.85.3.6482

[104] Chen SH, Kosai KI, Xu B, et al. Combination suicide and cytokine gene therapy for hepatic matastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 1996; 56: 3758-3762.

[105] Kieback DG, Fischer DC, Engehausen DG, et al. Intraperitoneal Ad-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer. Cancer Gene Ther. 2002; 9: 478-481. https://doi.org/10.1038/sj.cgt.7700462

[106] Qiu Z, Harms JS, Zhu J, Splitter GA. Bovine Herpes virus teguyment protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to herpes simplex virus VP22. J Virol. 2004; 78: 4224-4233. https://doi.org/10.1128/JVI.78.8.4224-4233.2004

[107] Mizuguchi H, Hayakawa T. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ther. 2002; 9: 236-242. https://doi.org/10.1038/sj.cgt.7700440

[108] Kagaya T, Nakamoto Y, Sakai Y, et al. Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer. Cancer Gene Ther. 2006; 13: 357-366. https://doi.org/10.1038/sj.cgt.7700908

[109] Zheng FQ, Xu Y, Yang RJ, et al. Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models. Acta Pharmacol Sin. 2009; 30(5): 617-627. https://doi.org/10.1038/aps.2009.33

[110] Yao X, Yoshioka Y, Eto Y, et al. TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection. Biochem Biophys Res Commun. 2007; 362: 419-424. https://doi.org/10.1016/j.bbrc.2007.08.001

[111] Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. 1999; 6: 57-62. https://doi.org/10.1038/sj.gt.3300810

[112] Wilder O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 1999; 59: 410-413.

[113] Wilder O, Morris JC. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses. J Gene Med. 2000; 2: 353-360. https://doi.org/10.1002/1521-2254(200009/10)2:5<353::AID-JGM130>3.0.CO;2-G

[114] Raki M, Hakkarainen T, Bauerschmitz GJ, et al. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic Ad. Gene Ther. 2007; 14: 1380-1388. https://doi.org/10.1038/sj.gt.3302992

[115] Wilder O, Morris JC. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res. 2000; 60: 4167-4174.

[116] Lambright ES, Amin K, Wiewrodt R, et al. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther. 2001; 8: 946-953. https://doi.org/10.1038/sj.gt.3301489

[117] Zhang JF, Wei F, Wang HP, et al. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J Exp Clin Cancer Res. 2010; 29(1):52. https://doi.org/10.1186/1756-9966-29-52

[118] Yee D, McGuire SE, Brünner N, et al. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther. 1996; 7(10): 1251-1257. https://doi.org/10.1089/hum.1996.7.10-1251

[119] Bonnekoh B, Greenhalgh DA, Bundman DS, et al. Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo. J Invest Dermatol. 1995; 104(3): 313-317. https://doi.org/10.1111/1523-1747.ep12664614

[120] Man J, Millican J, Mulvey A, Gebski V, Hui R. Response rate and survival at key timepoints with PD-1 blockade vs chemotherapy in PD-L1 subgroups: meta-analysis of metastatic NSCLC trials. JNCI Cancer Spectr. 2021; 5(3):pkab012. https://doi.org/10.1093/jncics/pkab012

[121] Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006; 98: 298-300. https://doi.org/10.1093/jnci/djj111

[122] Kuhn I, Harden P, Bauzon M, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One. 2008; 3(6):e2409. https://doi.org/10.1371/journal.pone.0002409

[123] Segerman A, Atkinson JP, Marttila M, et al. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol. 2003; 77: 9183-9191. https://doi.org/10.1128/JVI.77.17.9183-9191.2003

[124] Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med. 2003; 9: 1408-1412. https://doi.org/10.1038/nm952

[125] Rodríguez-García A, Giménez-Alejandre M, Rojas JJ, et al. Safety and efficacy of VCN-01, an oncolytic Adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clin Cancer Res. 2015; 21(6): 1406-1418. https://doi.org/10.1158/1078-0432.CCR-14-2213

[126] Bazan-Peregrino M, Garcia-Carbonero R, Laquente B, et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J Immunother Cancer. 2021; 9(11):e003254. https://doi.org/10.1136/jitc-2021-003254

[127] Garcia-Moure M, Martinez-Velez N, Gonzalez-Huarriz M, et al. The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models. Sci Rep. 2019; 9(1):14368. https://doi.org/10.1038/s41598-019-51014-1

[128] Martínez-Vélez N, Xipell E, Vera B, et al. The oncolytic adenovirus VCN-01 as therapeutic approach against pediatric osteosarcoma. Clin Cancer Res. 2016; 22(9): 2217-2225. https://doi.org/10.1158/1078-0432.CCR-15-1899

[129] Vera B, Martínez-Vélez N, Xipell E, et al. Characterization of the antiglioma effect of the oncolytic adenovirus VCN-01. PLoS One. 2016; 11(1):e0147211. https://doi.org/10.1371/journal.pone.0147211

[130] Heo J, Liang JD, Kim CW, et al. Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: phase I clinical trial. Mol Ther. 2023; 31(7): 2077-2088. https://doi.org/10.1016/j.ymthe.2023.04.006

[131] Ramesh N, Ge Y, Ennist DL, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res. 2006; 12(1): 305-313. https://doi.org/10.1158/1078-0432.CCR-05-1059

[132] Li R, Villa NY, Yu X, et al. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025; 31(1): 176-188. https://doi.org/10.1038/s41591-024-03324-9

[133] Knudsen ES, Nambiar R, Rosario SR, Smiraglia DJ, Goodrich DW, Witkiewicz AK. Pan-cancer molecular analysis of the RB tumor suppressor pathway. Commun Biol. 2020; 3(1): 158. https://doi.org/10.1038/s42003-020-0873-9

[134] Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol. 2004; 4: 595-602. https://doi.org/10.1038/nri1413

[135] Ahonen CL, Doxsee CL, McGurran SM, et al. Combined TLR and CD40 triggering induces potent CD8⁺ T cell expansion with variable dependence on type I IFN. J Exp Med. 2004; 199: 775-784. https://doi.org/10.1084/jem.20031591

[136] Cho HI, Celis E. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res. 2009; 69: 9012-9019. https://doi.org/10.1158/0008-5472.CAN-09-2019

[137] Peters PN, Whitaker RS, Lim F, et al. Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer. Neoplasia. 2024; 57:101056. https://doi.org/10.1016/j.neo.2024.101056

[138] Zheng H, Yu X, Ibrahim ML, et al. Combination IFNβ and membrane-stable CD40L maximize tumor dendritic cell activation and lymph node trafficking to elicit systemic T-cell immunity. Cancer Immunol Res. 2023; 11(4): 466-485. https://doi.org/10.1158/2326-6066.CIR-22-0927

[139] Enadenotucirev-expressing anti-CD40 agonistic monoclonal antibody NG-350A. In: NCI Drug Dictionary. National Cancer Institute; 2025. Accessed February 1, 2026. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/enadenotucirev-expressing-anti-cd40-agonistic-monoclonal-antibody-ng-350a

[140] Sasso MS, Snowden M, Lear R, et al. 1003 Tumor-specific replication and immunoactivity of aCD40-producing T-SIGn vectors. J Immunother Cancer. 2024; 12(suppl 2): A1–A1683. https://doi.org/10.1136/jitc-2024-SITC2024.1003

[141] Oncolytic adenovirus AdAPT-001. In: NCI Drug Dictionary. National Cancer Institute; 2025. Accessed February 1, 2026. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oncolytic-adenovirus-adapt-001

[142] Farzad L, Cerullo V, Yagyu S, et al. Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. Mol Ther Oncolytics. 2014; 1:14008. https://doi.org/10.1038/mto.2014.8

[143] Özcan AI, Aquino Lόpez A, Wolff AN, et al. Mesenchymal stromal cells protect combined oncolytic and helper-dependent adenoviruses from humoral immunity. Mol Ther Methods Clin Dev. 2024; 32(3):101279. https://doi.org/10.1016/j.omtm.2024.101279

[144] Zhang Q, Liu Z, Zhang J, et al. The efficacy of recombinant human adenovirus type 5 (H101) intra tumor therapy in persistent/recurrent/metastatic gynecological cancer and the exploration of changes in tumor microenvironment (Poster session, p 5536). Paper presented at: Gynecologic Cancer Poster Session, Oncology Meetings; 2024. Accessed February 1, 2026. https://s3.amazonaws.com/files.oncologymeetings.org/prod/s3fs-public/2024-05/AM24-Gynecologic-Cancer.pdf

[145] Musher BL, Rowinsky EK, Smaglo BG, et al. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024; 25(4): 488-500. https://doi.org/10.1016/S1470-2045(24)00079-2

[146] Fares J, Ahmed AU, Ulasov IV, et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncol. 2021; 22(8): 1103-1114. https://doi.org/10.1016/S1470-2045(21)00245-X

[147] Nassiri F, Patil V, Yefet LS, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med. 2025; 31(9): 3204. https://doi.org/10.1038/s41591-025-03895-1

[148] Virus DNX-2401 and temozolomide in recurrent glioblastoma. ClinicalTrials.gov, National Library of Medicine (US). Last updated March 2026. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT01956734

[149] Alonso MM, García-Moure M, Gonzalez-Huarriz M, et al. Oncolytic virus DNX-2401 with a short course of temozolomide for glioblastoma at first recurrence: clinical data and prognostic biomarkers. Paper presented at: Proceedings of the American Association for Cancer Research Annual Meeting; April 1–5, 2017; American Association for Cancer Research; 2017. Cancer Res. 2017;77(13 Suppl):CT027. https://doi.org/10.1158/1538-7445.AM2017-CT027

[150] Kudling TV, Haybout L, Clubb JH, et al. 514 Biomarker insights and long-term outcomes of TILT-123 oncolytic adenovirus combined with tumor-infiltrating lymphocytes in refractory metastatic melanoma: results from the TUNINTIL phase 1 trial. J Immunother Cancer. 2025; 13(suppl 2): A1–A1534. https://doi.org/10.1136/jitc-2025-SITC2025.0514

[151] Monberg TJ, Pakola SA, Albieri B, et al. Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma. Cell Rep Med. 2025; 6(3):102016. https://doi.org/10.1016/j.xcrm.2025.102016

[152] Block MS, Clubb JHA, Mäenpää J, et al. The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial. Nat Commun. 2025; 16(1): 1381; https://doi.org/10.1038/s41467-025-56482-w

[153] O'Cathail SM, Davis S, Holmes J, et al. A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiat Oncol. 2020; 15(1): 151. https://doi.org/10.1186/s13014-020-01593-5

[154] Garcia-Carbonero R, Bazan-Peregrino M, Gil-Martín M, et al. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. J Immunother Cancer. 2022; 10(3):e003255. https://doi.org/10.1136/jitc-2021-003255

[155] Phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine and plus/minus VCN-01 in patients with metastatic pancreatic cancer. ClinicalTrials.gov, National Library of Medicine (US). 2023. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT05673811

[156] Saltos AN, Arrowood C, Beasley GM, et al. 629-D The anti-tumor activity of IFNβ and membrane-stable CD40L expressing oncolytic virus MEM-288 in NSCLC patients is associated with modulation of the tumor microenvironment and systemic immune response. J Immunother Cancer. 2023; 11(suppl 2): A1687–A1817. https://doi.org/10.1136/jitc-2023-SITC2023.0629-D

[157] Naing A, Rosen L, Camidge RD, et al. 1011P FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: monotherapy dose escalation results. Ann Oncol. 2021; 32(Suppl 7): S853-S854. https://doi.org/10.1016/j.annonc.2021.08.1395

[158] Conley A, Williams J, Larson C, et al. 1523 AdAPT-001 in advanced soft-tissue sarcoma (BETA PRIME): a multicenter, open-label, phase 1 clinical trial. J Immunother Cancer. 2023; 11(suppl 2): A1732–A1867. https://doi.org/10.1136/jitc-2023-SITC2023.1523

[159] Oncolytic virus plus PD-1 inhibitor to patients with advanced pancreatic cancer. ClinicalTrials.gov, National Library of Medicine (US). 2025. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT06196671

[160] Observation of the efficacy and safety of oncolytic adenovirus (H101) combined with programmed death receptor inhibitors in treatment of advanced malignant pleural mesothelioma. ClinicalTrials.gov, National Library of Medicine (US). 2023. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT06031636

[161] Effect and safety of recombinant human adenovirus type 5 (H101) in advanced hepatocellular carcinoma patients with stable disease after sorafenib treatment: a randomized, parallel-controlled clinical trial. ClinicalTrials.gov, National Library of Medicine (US). 2022. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT05113290

[162] H101 combined with camrelizumab for recurrent cervical cancer. ClinicalTrials.gov. National Library of Medicine (US). 2022. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT05234905

[163] Oncolytic virus H101 combined with lenvatinib plus toripalimab compared with FOLFOX in patients with advanced biliary tract cancer (OPTIONS-06): a multicenter, randomized, phase 2 study. ClinicalTrials.gov. National Library of Medicine (US). 2025. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT06919848

[164] Recombinant human adenovirus type 5 plus HAIC of FOLFOX for intrahepatic cholangiocarcinoma. ClinicalTrials.gov. National Library of Medicine (US). 2022. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT05124002

[165] Oncolytic virus (H101) + SBRT + chemotherapy + targeted therapy + immunotherapy for unresectable colorectal cancer liver metastases (CRLM) (VVSHIP). ClinicalTrials.gov. National Library of Medicine (US). 2026. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT07381309

[166] A phase I study of multiple doses of neural stem cell-based oncolytic virotherapy (NSC-CRAd-S-pk7) administered intracerebrally to patients with recurrent high-grade gliomas. ClinicalTrials.gov. National Library of Medicine (US). 2025. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT05139056

[167] TNFα and IL-2 coding oncolytic adenovirus TILT-123 with lymphocyte-depleting chemotherapy and TILs in the treatment of metastatic melanoma. ClinicalTrials.gov, National Library of Medicine (US). 2025. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT06961786

[168] Oncolytic adenovirus TILT-123 and avelumab for treatment of solid tumors refractory to or progressing after anti-PD(L)1 (AVENTIL). ClinicalTrials.gov. National Library of Medicine (US). 2025. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT05222932

[169] A study of ONCOS-102 in combination with other novel immune-therapies in advanced treatment-resistant melanoma patients. ClinicalTrials.gov, National Library of Medicine (US). 2022. Accessed February 1, 2026. https://clinicaltrials.gov/study/NCT05561491

[170] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382): 1350-1355. https://doi.org/10.1126/science.aar4060

[171] Zaidi MR, Merlino G. The two faces of interferon-γ in cancer. Clin Cancer Res. 2011; 17(19): 6118-6124. https://doi.org/10.1158/1078-0432.CCR-11-0482

[172] Rožman P, Švajger U. The tolerogenic role of IFN-γ. Cytokine Growth Factor Rev. 2018; 41: 40-53. https://doi.org/10.1016/j.cytogfr.2018.04.001

[173] Acar C, Yüksel HÇ, Şahin G, et al. Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment. Discov Oncol. 2024; 15(1): 813. https://doi.org/10.1007/s12672-024-01702-w

[174] Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26): 2455-2465. https://doi.org/10.1056/NEJMoa1200694

[175] Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019; 30(7): 1080-1087. https://doi.org/10.1093/annonc/mdz135

[176] Shoushtari AN, Olszanski AJ, Nyakas M, et al. Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor microenvironment and clinical outcomes in anti-PD-1-resistant advanced melanoma. Clin Cancer Res. 2023; 29(1): 100-109. https://doi.org/10.1158/1078-0432.CCR-22-2046

[177] Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019; 5(9): 1276-1282. https://doi.org/10.1001/jamaoncol.2019.1478

[178] Chen C, Liu Y, Cui B. Effect of radiotherapy on T cell and PD-1 /PD-L1 blocking therapy in tumor microenvironment. Hum Vaccin Immunother. 2021; 17(6): 1555-1567. https://doi.org/10.1080/21645515.2020.1840254

[179] Tanaka K, Iwata T, Nishii K, et al. A case of primary pulmonary leiomyosarcoma completely resected after neoadjuvant chemotherapy. Surg Case Rep. 2019; 5(1): 91. https://doi.org/10.1186/s40792-019-0649-y

[180] Wang S, Duan H, Zhang X, Li B. Uterine leiomyosarcoma diagnosis after treatment of presumed uterine fibroid with the high-intensity focused ultrasound: a case description. Quant Imaging Med Surg. 2022; 12(6): 3489-3494. https://doi.org/10.21037/qims-21-814

[181] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-996. https://doi.org/10.1056/NEJMoa043330

[182] Brandes AA, Tosoni A, Franceschi E, et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2009; 64(4): 769-775. https://doi.org/10.1007/s00280-009-0926-8

[183] Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011; 91(3): 1071-1121. https://doi.org/10.1152/physrev.00038.2010

[184] Matuszewska K, Santry LA, van Vloten JP, et al. Combining vascular normalization with an oncolytic virus enhances immunotherapy in a preclinical model of advanced-stage ovarian cancer. Clin Cancer Res. 2019; 25(5): 1624-1638. https://doi.org/10.1158/1078-0432.CCR-18-0220ss

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.